Risperidone Use in Dementia Patients

Risperidone is a type of drug referred to as a second-generation antipsychotic. Since the introduction of the first antipsychotic drug in the 1950s, the search for better and safer antipsychotic medications has been the focus of neuropsychopharmacology for more than 50 years. Risperidone is an antipsychotic medication that was developed during this quest for an ideal medication to treat psychotic disorders. It was developed by Janssen Pharmaceutica in the 1980s. In 1993, the Food and Drug Administration (FDA) approved Risperidone for the treatment of schizophrenia. In 1994, the approval was extended to include the short-term treatment of mania associated with Bipolar I Disorder. In 2002, the FDA approved the dosage form of injectable Risperidone, which has a two-week dosing interval. Throughout the 1990s and 2000s, and through today, Risperidone continues to be widely studied, and important neuropharmacological research continues to be conducted on the drug so that the medical and scientific communities can gain a better understanding of its therapeutic risks and benefits. In fact, Risperidone is one of, if not the most well-researched antipsychotic medications to date. There is a wide array of published scientific and clinical data specific to Risperidone, as well as scientific and clinical data that compares it to other antipsychotic medications.

The global prevalence of dementia among older adults is estimated to be between 5% and 7%, and is increasing steadily every year. Demographic trends suggest a dramatic shift in the age distribution of the world's population over the coming decades. By 2050, the number of people aged 65 years and older is projected to nearly double, while the number of people aged 80 years and older is projected to triple. Because dementia risk increases markedly with age, the number of people with dementia is also expected to increase dramatically in the coming decades. Although population growth plays a role in the predicted increase in the number of people with dementia, demographic aging largely drives the increase.

Efficacy and Safety of Risperidone in Dementia Patients

Effectiveness of Risperidone in Managing Behavioral Symptoms

Three controlled studies and one open-label trial have shown that Risperidone is more effective compared to the usual care for behavioral symptoms such as agitation and aggression in patients with dementia of Alzheimer's type. The benefits of Risperidone on cognitive function and global changes in dementia symptoms were mixed in the open-label trial and in the case-control study conducted by Teri et al. and finished in

2000. Contrary evidence comes from the placebo-controlled trials. These were conducted by De Deyn et al. Street et al. in 1997, and Brodaty et al. in 2003, in which Risperidone was no better than a placebo in reducing behavioral symptoms.

Potential Adverse Effects of Risperidone in Dementia Patients

As Risperidone has been associated with increased adverse effects in the elderly, it is even more important to consider the individual patient's physical status and the medications they are taking. The common adverse effects include neuroleptic malignant syndrome, extrapyramidal symptoms, sedation, confusion, and postural hypotension. The first two may not present with classical features as the classic diagnostic criteria require an abnormal temperature, evidence of systemic toxicity, at least two out of four extrapyramidal features, and altered consciousness. Recognition of the adverse effects includes actively monitoring the patient when Risperidone is commenced, increasing the dose, and stopping the drug or switching the drug.

Comparison of Risperidone with Other Antipsychotic Medications

Risperidone's efficacy and safety have only been found to be moderate when directly compared to that of other antipsychotic medications. Risperidone 13.5 mg/day was found to be 1.5 times as effective as olanzapine 18.6 mg/day, according to one study that compared the two drugs' effectiveness in treating the symptoms of schizophrenia(ref). While Risperidone appears to be less effective when directly compared to other antipsychotic drugs, the medication does offer a favorable side effect profile, which many view as a significant upside to prescribing it to patients suffering from such conditions. Based on comparative effectiveness studies, practitioners may determine that Risperidone is not as efficacious in treating patients with symptoms of schizophrenia as other medications currently on the market. However, due to the decreased likelihood of labeling patients' results fatal, many will see the drug as an ideal option for treating this acute psychosis over prescribing other antipsychotic medications, which have proven in the past to lead to a course of detrimental side effects to the patient.

Ethical and Legal Implications of Risperidone Use in Dementia Patients

Informed Consent and Decision-Making Capacity

Someone with dementia may be unable to grasp the risks and benefits associated with a particular treatment, including Risperidone. This is particularly true in the advanced stages of the disease, by which point many individuals lose the ability to understand and retain information, weigh up the pros and cons of a situation, or communicate their decision. Such individuals are unable to provide informed consent to begin or continue specific treatments and thus enable a family member or legal guardian to make decisions on their behalf under a power of attorney.

Balancing Benefits and Risks in Treatment Decision

This is the reason as to why, due to the fact that such symptoms tend to pose a good deal of emotional and psychological stress to the caregivers. Patients' social functioning can also be considerably impaired, hence the need for treatment. Past studies have shown that a good percentage of people who take care of dementia patients experience health problems, too. Behavioral disturbances may pose a physical risk to the patient. It, however, varies across the patients as to whether treatment should be preferred. The FDA has also erected its opinion. Early mortality has also been noted in such patients, which means that they have a reduced likelihood of surviving. If the patients do not display temperament-related behaviors, they are less likely to receive any prescriptions. Therefore, these patent patients tend to harbor the highest benefits, meaning that the treatment for them needs to begin sooner. Talk to the caretaker about what treatment they can be allowed to make the patient feel better.

Bibliography

1. Clark, I. & Taylor, D. (2020). Newer formulations of risperidone: role in the management of psychotic disorders. CNS drugs. (https://link.springer.com/article/10.1007/s40263-020-00735-3)

2. Hodkinson, A., Heneghan, C., Mahtani, K. R., Kontopantelis, E., & Panagioti, M. (2021). Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. BMC medicine, 19, 1-15. (https://link.springer.com/article/10.1186/s12916-021-02062-w)

3. Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., ... & Liu, X. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, 7(2), e105-e125. (https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext?origen=app)

4. Yunusa, I. & El Helou, M. L. (2020). The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off .... Frontiers in Pharmacology. (https://www.frontiersin.org/articles/10.3389/fphar.2020.00596/full)

5. Magierski, R., Sobow, T., Schwertner, E., & Religa, D. (2020). Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Frontiers in pharmacology, 11, 1168. (https://www.frontiersin.org/articles/10.3389/fphar.2020.01168/full)

6. Beeber, A. S., Zimmerman, S., Wretman, C. J., Palmertree, S., Patel, K., & Sloane, P. D. (2022). Potential side effects and adverse events of antipsychotic use for residents with dementia in assisted living: implications for prescribers, staff, and families. Journal of Applied Gerontology, 41(3), 798-805. (https://journals.sagepub.com/doi/full/10.1177/07334648211023678)

7. Correll, C. U., Litman, R. E., Filts, Y., Llaudó, J., Naber, D., Torres, F., & Martínez, J. (2020). Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. npj Schizophrenia, 6(1), 37. (https://www.nature.com/articles/s41537-020-00127-y)

8. Zhao, M., Qin, B., Mao, Y., Zhang, Y., Zhao, R., Wang, A., ... & Wang, C. (2023). Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety. Neuropsychiatric Disease and Treatment, 749-757. (https://www.tandfonline.com/doi/pdf/10.2147/NDT.S407259)